Neuro Oncology 203 Media Kit Advertising & Sales Contacts Allan Kolstein Corporate Account Manager e: allan.kolstein@oup.com Caroline Bracken Supplements Development Manager t: +44 (0)865 353794 e: caroline.bracken@oup.com For reprints, eprints or tailored products: e: corporate.services@oup.com Official Journal of the Society for Neuro-Oncology since 997 Volume 4 Issue 7 July 202 glioblastoma page 89 idic(7)(p.2) in Neuro-Oncology is the leading journal in it s field, Neuro-Oncology is the official journal of the Society for Neuro-Oncology, the Japan Society for Neuro-Oncology, the European Association for Neuro-Oncology, and the World Federation of Neuro-Oncology Societies. Dedicated to providing superior and rapid publication of information in all areas of Neuro-Oncology, the journal contains peer-reviewed articles and reviews, symposia on selected topics, published abstracts of annual meetings, and society news and announcements from around the world. Useful Information Print Circulation:,680 Geographic Breakdown: North America 72% - Europe 0% - Japan % - Rest of World 7% Average Monthly Page Views: 44,000 Average Monthly Uniques: 3,200 Average Available Ad Impressions: 78,090* *Combined monthly leaderboard and skyscraper positions No. of etoc Subscribers: 07 Impact Factor: 5.723 Ranking: 5/9 Si: Clinical Neurology 22/94 Si: Oncology Journal Citation Reports (Science Citation Index, ISI) Target Audience: neurosurgeons, neuro-oncologists, and other specialists involved in the research, diagnosis, care and treatment of central nervous system tumors Frequency: 2 Peer Reviewed: Yes Editor-In-Chief: W. K. Alfred Yung M. D. Anderson Cancer Center Society Affiliation: Society for Neuro-Oncology Japan Society for Neuro-Oncology European Association of Neuro-Oncology
203 Schedule Volume Issue Cover Month Ad artwork due Mailout Date Bonus Conference Distribution 5/ January 2 December 202 6 January 203 5/2 February 4 January 203 4 February 203 5/3 March 29 January 203 March 203 5/4 April 4 March 203 3 April 203 5/5 May 5 April 203 7 May 203 5/6 June 3 May 203 4 June 203 5/7 July 3 June 203 28 June 203 5/8 August 2 July 203 30 July 203 5/9 September 3 July 203 3 September 203 5/0 October 30 August 203 27 September 203 SNO 2-24 November San Francisco 5/ November 9 October 203 7 November 203 5/2 December 30 October 203 26 November 203 Print Advertising Options & Rates Display Rates 203 x 3x 6x 2x Special Position Premiums Full Page 400 360 325 260 Full Page 2470 2430 2395 2330 ½ Page 65 35 05 050 ½ Page 2235 2205 275 220 ¼ Page 705 685 665 630 Cover 4-50% Cover 2-40% Cover 3-0% Facing Leading Article 0% ¼ Page 775 755 735 700 Facing Contents 0% Double Page Spread = 2 x Full page rate
Official Journal of the Society for Neuro-Oncology since 997 glioblastoma page 89 idic(7)(p.2) in Volume 4 Issue 7 July 202 Official Journal of the Society for Neuro-Oncology since 997 glioblastoma page 89 idic(7)(p.2) in Volume 4 Issue 7 July 202 Neuro-Oncology Advance Access published February 5, 202 Neuro-Oncology doi:0.093/neuonc/nor223 Terri S. Armstrong, Patrick Y. Wen, Mark R. Gilbert, and David Schiff Department of Integrative Nursing Care, UTHSC-SON (T.S.A.); Department of Neuro-Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas (T.S.A., M.R.G.); Center For Neuro-Oncology, Dana- Farber Cancer Institute and Division of Neuro-Oncology, Department of Neurology, Brigham and Women s Hospital, Boston, Massachusetts (P.Y.W.); Departments of Neurology, Neurological Surgery, and Medicine (Hematology-Oncology), University of Virginia, Charlottesville, Virginia (D.S.) Anti-angiogenic therapies, including bevacizumab, are being used with increasing frequency in the management of malignant glioma. Common clinically significant toxicities include hypertension and proteinuria, poor wound healing, and the potential for thromboembolic events. Literature related to the use of bevacizumab in malignant glioma, reported toxicities in this patient population, and management of these toxicities was reviewed. Recommendations for assessment and management are provided. Anti-angiogenic therapies will continue to have a role in the treatment of malignant glioma. Further studies of the prevention, assessment, and management of these toxicities are warranted. Keywords: brain tumors, chemotherapy, toxicity. alignant gliomas remain difficult to treat, and standard approaches are associated with poor survival. Despite level evidence of a survival benefit for those patients treated with concurrent temozolomide and radiation, followed by adjuvant temozolomide in patients with glioblastoma (GBM), the overall median survival, even with this therapy, was only 4.6 months. Even for patients who receive a diagnosis of anaplastic gliomas (World Health Organization [WHO] grade 3), median survival is only 2 4 years. 2 4 For all high-grade gliomas, achieving response after the tumor has recurred is difficult and Received October 4, 20; accepted November 7, 20. This is a summary of a Educational Sunrise Session presented at the Society of Neuro-Oncology Annual Meeting, Montreal, Quebec, Canada, November 200. Corresponding Author: Terri S. Armstrong, PhD, ANP-BC, 690 Bertner Ave, Houston, TX 77030 (terri.s.armstrong@uth.tmc.edu). survival is poor.in recurrent GBM, using temozolomide, response rates of 5% and 6-month progression-free survival of 2% have been reported. 5,6 Therefore, effective salvage therapies for patients with GBM are needed. Angiogenesis and Tumor Growth Previous preclinical and clinical investigations have established that most solid tumor growth beyond several millimeters is dependent on angiogenesis. 7,8 Angiogenesis is a physiologic process involving a balance of angiogenic factors and inhibitors that control microvessel sprout growth and proliferation of endothelial cells. 9 The importance of this increased vasculature in glioma was first observed by Virchow during the 9th century 0, and was recognized to be integral to tumor growth. The profound importance of angiogenesis in brain tumor biology is highlighted by the recognition that endothelial proliferation is a hallmark of GBM and is considered to be a major criterion in conferring the histopathological diagnosis. GBM cells are known to produce angiogenic factors, such as basic fibroblast growth factor, hepatocyte growth factor/ scatter factor, and vascular endothelial growth factor-a (VEGF-A). 3 In addition, endothelial cells in tumor express VEGFR2 (KDR), resulting in a paracrine loop. These signaling pathways work with other important pathways and glioma stem-like cells to result in new vessel formation supporting continued tumor growth. Anti-Angiogenic Therapy Because of the importance of vascular proliferation in the biology of GBM, targeting angiogenesis may be an # The Author(s) 202. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. Incentives Agency Commission 5% More options and solutions in partnership with Neuro-Oncology Loose and Bound Inserts available Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors M Downloaded from http:/// at OUP site access on August 3, 202 Belly Band Sponsored supplements published and distributed with the journal Article reprints and eprints useful as conference handouts
Online Advertising Options & Rates Advertise on Online rates Type Size (pixels) Run of Site* Geo-targeted* Leaderboard 728 x 90 $70 CPM $80 CPM Skyscraper 60 x 600 $70 CPM $80 CPM *Minimum order 0,000 impressions. Leaderboard Advertise on table of contents alerts Reach a highly engaged opted in audience of over,000 Professionals exclusively. Skyscraper etoc Your ad here etoc Rates & Sizes $400 per 000 registrants (min. charge $400) Skyscraper: 60 x 600 pixels TARGET YOUR AD By country, region, and or therapy area. MAXIMUM IMPACT Integrate digital advertising with an ad in the print copy of the journal. TRACK RESPONSE In-depth online reports available
Print Specifications Size (depth x width) Bleed Trim Type area Full Page 286mm x 26mm ( ¼ x 8 ½ ) 276mm x 20mm (8 /4 x 0 7/8 ) 255mm x 78mm (0 /6 x 7 ) Half Page Landscape 20mm x 78mm (4 ¾ x 7 ) Half Page Vertical 255mm x 85mm (0 /6 x 3 /6 ) Quarter Page 20mm x 85mm (4 ¾ x 3 /6 ) Double Page Spread - Please supply as two separate full page files PDF specifications: PDF files should be created using Adobe Acrobat Distiller 4.0 or higher. Files should be composite PDFs, not separated. All fonts and images should be embedded and subset below 00%. All mono and color ads should have an effective resolution of 300 dpi (minimum). Color ads should be supplied as CMYK only (e.g. no RGB, Lab color, ICC color based or Pantone Color). Monochrome bitmap images (line-art) should have an effective resolution of 200 dpi. Half-tone dot range should be in the range of 3% to 95%. Ads set to the type area should be surrounded by a box, and have no registration marks or catchlines. Bleed ads should have crop marks set to the trim size dimensions, and will be trimmed accordingly. Please allow 3mm bleed on all four sides. Any vector-based objects with transparency effect must be rasterized to 600 dpi in the source file itself, before creating the PDF. For more information on technical specifications, please contact us. All advertisements are subject to the approval of the Publisher and/or Editor who reserves the right to reject or cancel any advertisement at any time.